Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL | Dr Jacqueline Barrientos at Annual Meeting 2015 - 101271

Spotlight
Video

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL | Dr Jacqueline Barrientos at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that evaluated the safety and efficacy of the PI3Kδ inhibitor, idelalisib, in combination with chemoimmunotherapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Investigated combinations include idelalisib in combination with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 07/21/15
Added : 4 years ago